glp-1 rebound weight gain Reduction with Agonists and Paths for Discontinuation While Maintaining Weight Loss November Blog - What happens

MHRAs chief safety officer Alison Cave said, The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms. She said that for a majority of patients, GLP-1s are safe and effective medicines which deliver significant health benefits

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

Liraglutide In the LEAN study, the treatment efficacy and safety of the once-daily liraglutide (1.8 mg) were compared with those of the placebo after 48 weeks in 52 overweight patients with clinical evidence of NASH [12]

Questions: Please reach out to your Medical Provider at your clinic

Annals of Medicine and Surgery